Diaclone, a leading player recognized for its expertise in the fields of inflammation, oncology and immunology, has been handed over to its Finnish counterpart Medix Biochemica, owned by the investment fund DevCo Partners.
Diaclone offers best-in-class monoclonal antibodies, high quality ELISA and ELISPOT kits as well as custom services – ranging from immunoassay kit development to new antibody discovery using hybridoma and phage display technologies – to a broad range of IVD, life science, and pharma customers.
Medix Biochemica, a global leader in critical IVD raw materials, has acquired 100 percent of the shares of Diaclone from Biotech Investissement Group. As a result of the acquisition, Medix Biochemica broadens its portfolio of critical raw materials for the in vitro diagnostics (“IVD”) industry, complements its scientific expertise and strengthens its local presence in Western Europe. Diaclone will become an important part of the Immunodiagnostic Reagents Business Unit within Medix Biochemica’s group structure, and its high-quality operations will continue in Besançon, France.
“The acquisition of Diaclone is an important step towards our vision to be the first-choice, independent raw material partner for the IVD industry. The portfolio of Diaclone, including several gold standard antibodies, complements the offering of Medix Biochemica very well, and we are excited about the opportunity to offer these productsto our global customer base. In addition, we see an excellent strategic and cultural fit with Medix Biochemica, and we value Diaclone’s technical and scientific competence highly. We look forward to jointly developing innovative and high quality products to support our customers even better in the future.”, says Steve Ferguson, CEO of Medix Biochemica.
“Following careful consideration, we concluded that it is the right time to find a new partner to support Diaclone’s future international growth. We are convinced that Medix Biochemica with its comprehensive reach to IVD customers globally, strong focus on quality and R&D and clear long-term vision, is the optimal new partner for Diaclone.”, says Philippe Dulieu, President of Biotech Investissement Group.
With this transaction, DDA & Company once again provides evidence of its expertise in niche cross-border transactions: “By conducting a process focused on a very targeted number of candidates, we received many high quality offers and were able to select the project proposed by Medix Biochemica which met all of our client’s criteria.“, said Anthony Wimbush, Director at DDA & Company.
DDA & Company advised Diaclone in this transaction with a team consisting of Alexandre Odin, Anthony Wimbush and Charles-Antoine Cayez.
Stakeholders in this Transaction
- Diaclone: Managers (Philippe Dulieu)
- M&A advisors: DDA & Company (Alexandre Odin, Anthony Wimbush, Charles-Antoine Cayez)
- Legal: Franklin (Yam Atallah, Vincent Lehmann)
- Medix Biochemica: Managers (Steve Fergusson, Manuel Liedot, Isabelle Bouyenval)
- DevCo Partners: Teemu Alahuhta (Matias Karioja)
- Legal: DLA Piper (Sarmad Haidar, Anthony Guillaume, Lea Kemayou, Alexandre Balducci)
- Financial & Tax Due Diligence: EY (François Poncet, Louis Jeanne, Li Wang, Joonas Juvonen)